Boehringer Pledges $358M, Up to $7B More, for 6 Sino Cancer Programs

Boehringer Ingelheim has signed a second cancer partnership with Sino Biopharmaceutical, the drugmaker known as SBP Group. The German company gets options on six early cancer programs. SBP Group will receive US$358 million in upfront and near-term payments, the companies said on Nov. 4.

What happened

The deal covers six biologic programs that have not yet reached human testing. They use two technologies: antibody-drug conjugates (ADCs) and T-cell engagers. Boehringer did not name the targets or the diseases.

• Money: beyond the US$358 million, SBP Group can earn up to US$7 billion in option, development, regulatory and sales milestones. It is also eligible for tiered royalties of up to double digits on future sales.
• Where the drugs come from: five programs are from LaNova Medicines in Shanghai, which SBP Group fully owns. The sixth is from Beijing Tide Pharmaceutical, another SBP Group company.
• Who does what: SBP Group runs early development. Once agreed clinical milestones are met, Boehringer can take exclusive rights to develop, make and sell the drugs.
• Territory: for four programs, Boehringer's rights would cover the world outside mainland China, Hong Kong and Macau. For the other two, the rights would be worldwide.

Paola Casarosa, who heads Boehringer's innovation unit, said the deal puts the company's China strategy into action. BioPharm International, citing Reuters, reported that SBP shares rose about 5% in Hong Kong after the news.

Why it matters

Boehringer is making a large commitment to programs from China before any of them has been tested in people. Most of the value depends on milestones, so the final payout could be far lower than the headline figure.

It also builds on earlier ties. In April 2024, SBP agreed to help develop and sell several Boehringer cancer drugs in mainland China, BioPharm International reported. Boehringer said its newly opened China research and development site in Shanghai widens its early clinical and partnering work.

The two technologies are a clear focus for Boehringer. According to BioPharm International, the company licensed an ADC from AimedBio in October 2025 in a deal worth up to $991 million. Casarosa has named ADCs and T-cell engagers as the key focus of its cancer deals.

What it means for people in the industry

Neither source mentions new jobs or sites in the US or Canada. SBP Group will run the early development of these programs. For discovery and business development staff, the deal shows the terms one large drugmaker accepted for early programs from China.

Things to watch: whether Boehringer names the targets, and when the first program reaches the clinical milestones that trigger an option. Those steps will show how much of the US$7 billion is likely to be paid.

See open pharma jobs in the US and Canada

Sources

• Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies, Boehringer Ingelheim (press release via GlobeNewswire)
• Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion, BioPharm International